









Markets
/
Stocks
/
nasdaq-mdgl
/

Madrigal Pharmaceuticals Inc

MDGL

495.910USD

-3.260-0.65%

Close 01/27, 16:00（ET）Quotes delayed by 15 min

11.26BMarket Cap

LossP/E TTM



Madrigal Pharmaceuticals Inc

495.910

-3.260-0.65%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Madrigal Pharmaceuticals Inc

Currency: USD Updated: 2026-01-26

Key Insights

Madrigal Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 22 out of 394 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 628.40.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Madrigal Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

22 / 394

Overall Ranking

98 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Madrigal Pharmaceuticals Inc Highlights

StrengthsRisks

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 180.13M.

Undervalued

The company’s latest PE is -38.66, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 21.93M shares, decreasing 9.21% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 24.48K shares of this stock.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

415.786

Target Price

+25.53%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-01-26

The current financial score of Madrigal Pharmaceuticals Inc is 8.16, ranking 59 out of 394 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 287.27M, representing a year-over-year increase of 362.03%, while its net profit experienced a year-over-year increase of 6.76%.

Score

Industry at a Glance

Previous score

8.16

Change



Financials

6.76

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.40

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Madrigal Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-01-26

The current valuation score of Madrigal Pharmaceuticals Inc is 7.21, ranking 153 out of 394 in the Biotechnology & Medical Research industry. Its current P/E ratio is -38.66, which is -88.57% below the recent high of -4.42 and -20.77% above the recent low of -46.69.

Score

Industry at a Glance

Previous score

7.21

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 22/394

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-01-26

The current earnings forecast score of Madrigal Pharmaceuticals Inc is 8.12, ranking 161 out of 394 in the Biotechnology & Medical Research industry. The average price target is 557.00, with a high of 650.00 and a low of 456.00.

Score

Industry at a Glance

Previous score

8.12

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 17 analysts

Buy

Current Rating

628.400

Target Price

+30.79%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

541

Total

Median

Average

Company name

Ratings

Analysts

Madrigal Pharmaceuticals Inc

MDGL

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

...

108

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-01-26

The current price momentum score of Madrigal Pharmaceuticals Inc is 7.02, ranking 173 out of 394 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 583.01 and the support level at 440.65, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.78

Change

0.24

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-7.059

Sell

RSI(14)

39.748

Neutral

STOCH(KDJ)(9,3,3)

60.345

Buy

ATR(14)

22.112

Low Volatility

CCI(14)

-47.474

Neutral

Williams %R

72.250

Sell

TRIX(12,20)

-0.633

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

495.004

Buy

MA10

497.666

Sell

MA20

530.721

Sell

MA50

554.237

Sell

MA100

498.261

Sell

MA200

408.350

Buy

Institutional Confidence

Currency: USD Updated: 2026-01-26

The current institutional shareholding score of Madrigal Pharmaceuticals Inc is 10.00, ranking 1 out of 394 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 96.57%, representing a quarter-over-quarter decrease of 0.25%. The largest institutional shareholder is John Paulson, holding a total of 1.91M shares, representing 8.40% of shares outstanding, with 11.67% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

2.14M

RTW Investments L.P.

1.99M

Paulson & Co. Inc.

Star Investors

1.91M

-8.71%

Janus Henderson Investors

1.84M

-15.93%

Avoro Capital Advisors LLC

1.83M

-2.24%

The Vanguard Group, Inc.

Star Investors

1.81M

-3.49%

BlackRock Institutional Trust Company, N.A.

1.34M

+6.62%

State Street Investment Management (US)

658.10K

-4.72%

SQN, L.L.C.

655.54K

Geode Capital Management, L.L.C.

446.23K

+7.68%

Risk Assessment

Currency: USD Updated: 2026-01-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Madrigal Pharmaceuticals Inc is 7.08, ranking 18 out of 394 in the Biotechnology & Medical Research industry. The company's beta value is -1.02. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.